BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35670704)

  • 1. Asparaginase
    Gao C; Ma X; Zhang Z; Lu Q; Ashby CR; Wei L; Chen ZS
    Drugs Today (Barc); 2022 Jun; 58(6):261-271. PubMed ID: 35670704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?
    Maese L; Rizzari C; Coleman R; Power A; van der Sluis I; Rau RE
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29169. PubMed ID: 34105243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
    Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
    Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers.
    Lin T; Hernandez-Illas M; Rey A; Jenkins J; Chandula R; Silverman JA; Choi MR
    Clin Transl Sci; 2021 May; 14(3):870-879. PubMed ID: 33278328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperinsulinism-induced hypoglycemia secondary to asparaginase Erwinia chrysanthemi (recombinant)-rywn chemotherapy in a pediatric AML patient.
    Carlo A; Watson A; Klein G; Ghanny S; Tell S; Horowitz T; Siver M; Appel B; Chen J
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30914. PubMed ID: 38321590
    [No Abstract]   [Full Text] [Related]  

  • 6. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study.
    Maese L; Loh ML; Choi MR; Lin T; Aoki E; Zanette M; Agarwal S; Iannone R; Silverman JA; Silverman LB; Raetz EA; Rau RE
    Blood; 2023 Feb; 141(7):704-712. PubMed ID: 36108304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP-458).
    Lin T; Dumas T; Kaullen J; Berry NS; Choi MR; Zomorodi K; Silverman JA
    Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1503-1513. PubMed ID: 34310867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management.
    Sandley M; Angus J
    Leuk Lymphoma; 2023 Apr; 64(4):776-787. PubMed ID: 36781296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase (JZP458) in patients with acute lymphoblastic leukemia.
    Lin T; Whigham T; Fernando I; Choi MR; Wang Q; Silverman JA
    Clin Transl Sci; 2023 May; 16(5):898-909. PubMed ID: 36929533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
    Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
    Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase
    Tong WH; Rizzari C
    Haematologica; 2023 Oct; 108(10):2606-2615. PubMed ID: 37470157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asparaginase (Erwinia chrysanthemi) (Recombinant)-rywn.
    Am J Health Syst Pharm; 2021 Oct; 78(21):1919-1921. PubMed ID: 34492097
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
    Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
    Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
    Duval M; Suciu S; Ferster A; Rialland X; Nelken B; Lutz P; Benoit Y; Robert A; Manel AM; Vilmer E; Otten J; Philippe N
    Blood; 2002 Apr; 99(8):2734-9. PubMed ID: 11929760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
    Feldman K; Aaronson K; Gu T; Ige K; Southworth E; Sanchez L; Stieglitz E
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30891. PubMed ID: 38311802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
    Vrooman LM; Supko JG; Neuberg DS; Asselin BL; Athale UH; Clavell L; Kelly KM; Laverdière C; Michon B; Schorin M; Cohen HJ; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2010 Feb; 54(2):199-205. PubMed ID: 19672973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
    Figueiredo L; Cole PD; Drachtman RA
    Expert Rev Hematol; 2016 Mar; 9(3):227-34. PubMed ID: 26765930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
    Ogawa C; Taguchi F; Goto H; Koh K; Tomizawa D; Ohara A; Manabe A
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28244643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
    Billett AL; Carls A; Gelber RD; Sallan SE
    Cancer; 1992 Jul; 70(1):201-6. PubMed ID: 1606543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.